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Introduction
Interleukin (IL)-18 is a pro-inflammatory member of the IL-1
cytokine family that is constitutively expressed primarily in 
monocytes/macrophages, neutrophils and epithelial cells [1–3].
This cellular pattern of expression suggests a key role of IL-18 in
the cytokine network orchestrating innate immune activation and
successive acquired immunity. The function of IL-18 in immunity
is mediated by its capability to rapidly initiate an inflammatory
cytokine cascade [4, 5] and to act as potent co-stimulus for 
production of interferon (IFN)- [1–3]. In concurrence with its
pro-inflammatory nature, IL-18 production has been linked to
severity of disease in models of inflammation such as experimen-
tal colitis [6] and arthritis [7]. Accordingly, up-regulation of IL-18
is detectable in inflammatory syndromes in patients [3].
Due to inherent pathogenicity in association with constitutive
expression in cells of the innate immune system, control of IL-18
bioactivity is a major objective of immunoregulation. Two principal
checkpoints are in place. One is pro-IL-18 maturation by caspase-1
[3]. The second modulatory principle is suppression of IL-18
function by its natural antagonist, IL-18 binding protein (IL-18BP)
[8–10]. IL-18BP is a circulating decoy receptor able to bind to and
inactivate IL-18 biological activity. Of the four isoenzymes of
human IL-18BP, IL-18BPa and IL-18BPc neutralize IL-18 with high
efficacy. IL-18BPa is by far the most abundant splice variant in
human cDNA libraries [8, 11] and thus is concentrated on and
referred to as IL-18BP throughout the study. IL-18BP is constitu-
tively expressed in the spleen [8] thereby establishing a physiolog-
ical buffer directed against unwanted basal IL-18 bioactivity that
may arise from dying cells. Notably, IL-18BP is up-regulated by
immunoactivation as seen in sepsis [12] and under conditions of
chronic inflammation such as Crohn’s disease [13], psoriasis [14]
and Wegener’s granulomatosis [15]. The significance of the 
IL-18/IL-18BP system is furthermore highlighted by the existence
of viral forms of IL-18BP that are secreted by infected cells and
likely contribute to the pathophysiology of infection. For exam-
ple, expression of vIL-18BP may mediate the phenomenon of
absent inflammation in the context of infection by the molluscum
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contagiosum virus [16]. We and others have previously identi-
fied IFN- as chief mediator of IL-18BP induction. Interestingly,
induction of IL-18BP appears to especially apply to non-leucocytic
cells [17–20] and could be demonstrated in the ex vivo setting of
colonic organ cultures [18]. Notably, this regulatory path operates
in vivo [21] and may curb IL-18 biological activity as part of a neg-
ative feedback loop [10]. In the present study, we set out to inves-
tigate molecular mechanisms that direct expression of IL-18BP in
human DLD-1 colon carcinoma cells under the influence of IFN-.
Materials and methods
Reagents
IFN- was from Peprotech (Frankfurt, Germany), IL-1 receptor antagonist
(IL-1Ra) from R&D Systems (Wiesbaden, Germany), IL-1 from Invitrogen
(Solingen, Germany) and Cycloheximide (CHX) from Sigma (Taufkirchen,
Germany). Tumour necrosis factor (TNF)- was kindly provided by the Knoll
AG (Ludwigshafen, Germany).
Cultivation of DLD-1 colon carcinoma cells,
freshly isolated peripheral blood mononuclear
cells (PBMC) and monocytic THP-1 cells
DLD-1 cells (Center of Applied Microbiology and Research, Salisbury, UK)
were maintained in Dulbecco’s modified eagle medium (DMEM) supple-
mented with 100 U/ml penicillin, 100 g/ml streptomycin and 10% heat-
inactivated foetal bovine serum (FCS; GIBCO-BRL, Eggenstein, Germany).
Unless otherwise indicated, cells were incubated under the specified experi-
mental conditions on polystyrene plates (Greiner, Frickenhausen, Germany)
in the aforementioned culture medium. The study protocol and consent doc-
uments for isolation of PBMC from healthy donors were approved by the
‘Ethik Kommission’ of the Klinikum der Johann Wolfgang Goethe-
Universität. Informed consent was obtained from volunteers. Healthy donors
abstained from using drugs during 2 weeks before the study. PBMC were
freshly isolated using Histopaque
®-1077 (Sigma). PBMC were resuspended
in Roswell Park Memorial Institute (RPMI) 1640 supplemented with 10 mM
HEPES, 100 U/ml penicillin, 100 g/ml streptomycin and 1% heat-
inactivated human serum (Invitrogen, Karlsruhe, Germany) and seeded at 3 
10
6 cells/ml in round-bottom polypropylene tubes (Greiner, Frickenhausen,
Germany). Monocytic THP-1 cells were obtained from the German Collection
of Microorganisms and Cell Cultures (Braunschweig, Germany). Cells were
maintained and stimulated in RPMI 1640 supplemented with 10 mM HEPES,
100 U/ml penicillin, 100 g/ml streptomycin and 10% heat-inactivated FCS
(GIBCO-BRL) using polystyrene flasks and plates (Greiner). All incubations
of cell cultures were performed at 37C and 5% CO2.
Detection of IL-18BP, interferon regulatory factor
(IRF)-1 and signal transducer and activator of
transcription-1 (STAT1) by immunoblot analysis
For detection of secreted IL-18BP (cultivation of cells without FCS), cell-free
supernatants were trichloroacetic acid (TCA) precipitated, as previously
described [18]. To detect total STAT1, activated phosphorylated pSTAT1,
and IRF-1, nuclear extracts of DLD-1 cells were isolated as previously
described [22]. For detection of total nuclear STAT1, blots were stripped and
reprobed. Antibodies: IL-18BPa, goat polyclonal antibody (R&D Systems);
total STAT1, rabbit polyclonal antibody (Santa Cruz Biotechnology,
Heidelberg, Germany); pSTAT1-Y701, rabbit polyclonal antibody (Cell
Signaling, Frankfurt, Germany); IRF1, rabbit polyclonal antibody (Santa
Cruz Biotechnology) and -actin, mouse monoclonal antibody (Sigma).
Luciferase reporter assays
An IL-18BP promoter fragment was cloned into pGL3-Basic (Promega,
Mannheim, Germany) and entitled pGL3-BPwt. Position of cloned DNA,
AF110798: nt128-nt794 (667 nt long, spanning until –657 bp relative to the
transcriptional start site at nt785 of AF110798). The following primers were
used for cloning of pGL3-BPwt: forward, 5	- TCTTACGCGTGTCTTGGAGCTC-
CTAGAGGGA-3	 reverse, 5	-TCGCAGATCTGCTTCTGGGAAGGGCAG-3	. Site
directed mutagenesis was performed by using the QuikChange site-directed
mutagenesis kit (Stratagene, Amsterdam, Netherlands) in order to generate
promoter fragments that show a dysfunctional proximal -activated
sequence (GAS) (pGL3-BPmt/prox, located at –25 bp to –33 bp), a dysfunc-
tional putative distal GAS site (pGL3-BPmt/dist, located at –625 bp to –633
bp) and a double mutation of both GAS sites (pGL3-BPmt/dist/prox). The 
following primers were used for that purpose: pGL3-BPmt/dist, forward:
5	-TAGAGGGAAGCGAT TGGAAAGGAAGGCTCT-3	; pGL3-BPmt/prox, for-
ward: 5	-GGCAGTGCTGATATCGAAGGATTGCTC-3	. The identity of the
mutants was confirmed by sequencing. For each transfection experiment (on
six-well polystyrene plates) 1 g of the indicated plasmids were transfected
using Lipofectamine2000 (Invitrogen). For control of transfection efficiency
0.1 g pRL-TK (Promega) coding for Renilla luciferase were cotransfected.
After 4 hrs of transfection, culture medium was exchanged and DLD-1 cells
were rested for 20 hrs. Thereafter, cells were either kept as unstimulated con-
trol or stimulated with IFN- (20 ng/ml). After another 6-hr stimulation
period, cells were harvested and fold induction of luciferase activity by 
IFN- was determined by using the dual reporter gene system (Promega)
with control conditions (unstimulated cells transfected with the same
respective promoter fragment) set to 1.
Electrophoretic mobility shift assay 
(EMSA analysis)
Preparation of nuclear extracts was performed as previously described
[22]. A double-stranded oligonucleotide reflecting the specific proximal
GAS site at the IL-18BP promoter was used for EMSA analysis: EMSA/GAS
oligonucleotide (–18 bp to –40 bp relative to the IL-18BP transcriptional
start site [20]): 5	-CAGTGCTTTCCCAGAAGGATTGC-3	. In addition, two
oligonucleotides with mutations at the specific proximal GAS site were
used to further characterize the retarded complex and are entitled:
GASprox-5	mut: 5	-CAGTGCTGATATCGAAGGATTGC-3	; GASprox-3	mut:
5	-CAGTGCTTTCCCATCCGGATTGC-3	. Complementary oligonucleotides
were labelled by T4 polynucleotide kinase (MBI Fermentas, St. Leon-Rot,
Germany) using [-
32P]ATP (6000 Ci/mmol, Amersham Bioscience,
Braunschweig, Germany). Binding reactions were performed for 45 min. on
ice with either 5 g (Fig. 2C, left panel) or 1 g of protein (Fig. 2C, right panel)
in 20 l of buffer containing 4% Ficoll, 20 mM n-2-hydroxyethylpiperazine-
n	-2-ethane sulfonic acid (HEPES) (pH 7.9), 50 mM KCl, 1 mM ethylenedi-
aminetetraacetic acid, 1 mM DTT, 1 mM phenylmethanesulfonylfluoride
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(PMSF), 0.25 mg/ml bovine serum albumin, 1.25 g of poly(dI-dC) and
50.000 cpm of 
32P-labelled oligonucleotide. To characterize retarded com-
plexes, nuclear proteins were pre-incubated (30 min., RT) with two different
rabbit polyclonal anti-STAT1 antibodies (Santa Cruz Biotechnology and
Upstate Biotechnology, Hamburg, Germany).
Chromatin immunoprecipitation (ChIP analysis)
After fixation (RT, 10 min., 1% formaldehyde) and addition of glycine-buffer,
cells were harvested in phosphate buffered saline (PBS)/PMSF (1 mM) fol-
lowed by incubation in lysis-buffer, supplemented with PMSF (1mM) and
proteinase inhibitor cocktail (Enzymatic Shearing Kit, Active Motif,
Rixensart, Belgium). After 30 min. on ice, douncing and centrifugation
(15,000  g, 4C, 10 min.), nuclei were resuspendend in digestion buffer.
Genomic DNA was digested by adding enzymatic shearing-cocktail solu-
tion (200 U/ml). After addition of 20 l 0.5 M EDTA, 10 min. on ice and
centrifugation, 1/10 of the digested genomic DNA was removed for control
of shearing efficiency and PCR-input, respectively. Nine out of 10 of the
digested DNA-protein-complexes were immunoprecipitated either with 3
g of IgG control or STAT1 antibody (Santa Cruz). After washing in
PBS/RIPA-buffer (10 mM Tris-HCl, pH 8.0, 140 mM NaCl, 1% triton-X-100,
0.1% SDS), DNA-protein complexes were eluted from the beads twice by
200 l of 1% SDS (in TE-buffer) and 200 l of 0.67% SDS (in TE-buffer)
at 65C (10 min.). After RNase (4 hrs, 65C) and proteinase K (2 h, 42C)
digestion, sheared genomic DNA was precipitated. To amplify the IL-18BP
promoter fragment containing the GAS site under investigation (–25 bp to
–33 bp relative to the IL-18BP transcriptional start site [20]), the following
primers were used: forward, 5	-GCTGAAGGTTTCTGGCCA-3	; reverse, 5	-
TAGCCTGGAGCTCTT TCA-3	. PCR conditions: 95C for 10 min. (1 cycle);
95C for 30 sec., 54C for 30 sec. and 72C for 1 min. for 40 cycles, and a
final extension phase at 72C for 7 min. Identity of amplicons (360 bp) was
confirmed by sequencing (AbiPrism 310 Genetic Analyzer, Applied
Biosystems, Darmstadt, Germany).
Analysis of IL-18BP by quantitative realtime PCR
Realtime PCR for IL-18BP and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was performed as previously described [22]. Primers and probe
for IL-18BPa were designed using Primer Express (Applied Biosystems)
according to AF110798: forward, 5	-ACCTCCCAGGCCGACTG-3	; reverse,
5	-CCTTGCACAGCTGCGTACC-3	; probe 5	-CACCAGCCGGGAACGTGGGA-
3	. Amplification of genomic DNA was avoided by selecting an amplicon
that crosses an exon/intron boundary. For GAPDH pre-developed assay
reagents were used (4310884E; Applied Biosystems). Quantitative realtime
PCR was performed on AbiPrism 7700 Sequence Detector (Applied
Biosystems): One initial step at 50C for 2 min. and 95C for 2 min. was
followed by 40 cycles at 95C for 15 sec. and 60C for 1 min. Detection,
calculation of threshold cycles (Ct values) and data analysis were per-
formed by Sequence Detector software. mRNA was quantified by use of
cloned cDNA standards for IL-18BP and GAPDH. Data for IL-18BP were
normalized to those of GAPDH.
Suppression of STAT1 and IRF1 expression by siRNA
For experiments, DLD-1 cells were transfected with 100 nM of either STAT1
siRNA (SI02662324, Qiagen, Hilden, Germany), IRF1 siRNA (5	-AGACCA-
GAGCAGGAACAAGTTdtdt-3	, MWG), or control siRNA (Silencer®Negative
Control siRNA, #4611, Ambion) using Lipofectamine2000 (Invitrogen). 
All cultures without siRNA or control siRNA were mock transfected. After
48 hrs, cells were further stimulated with IFN- and harvested thereafter
for further analysis. Transfection of siRNA (control; STAT1 or IRF1 target-
ing) by the experimental protocol used herein did not mediate activation of
IRF3 in DLD-1 cells indicating that the procedure was not associated with
cellular activation induced by RNA sensing mechanisms of innate immu-
nity (data not shown).
Determination of IL-8 release by enzyme-linked
immunosorbent assay (ELISA)
IL-8 in cell-free supernatants was determined by ELISA according to the
manufacturer’s instructions (BD Biosciences, Heidelberg, Germany).
Statistical analysis
Data are shown as means 
 S.D. and are presented as ng/ml, as fold
induction compared with unstimulated control, or as percent of IFN-
alone. Raw data were analysed by one-way ANOVA with post hoc Bonferroni
correction (GraphPad 4.0).
Results
Optimal induction of IL-18BP in DLD-1 cells 
is dependent on protein translation
In previous work, we identified IFN- as a potent stimulus for pro-
duction of IL-18BP [17–19], particularly in non-leucocytic cells
(Table 1). The crucial role of signal transduction pathways that are
activated by IFN- is underscored by the observation that IL-18BP
secretion cannot be initiated by the combination IL-1/TNF-
(Fig. 1A), although those cytokines are particularly efficient in acti-
vating DLD-1 cells, e.g. for IL-8 secretion (Fig. 1D). To clarify
whether full induction of IL-18BP mRNA requires de novo protein
synthesis, cells were activated in the presence of the translational
inhibitor CHX. Figure 1B demonstrates that protein synthesis is
mandatory for optimal mRNA induction, even though significant
up-regulation of IL-18BP can be achieved upon blockage of trans-
lation. Notably, under those conditions, induction of IRF1, a cru-
cial component of the IFN- response [23], was suppressed in
cells exposed to CHX (Fig. 1B, inset). Recently, it has been pro-
posed that endogenous IL-1 contributes to immunoregulatory
actions of IFN-, including up-regulation of IL-18BP in epithelial-
like cells [21]. To identify a potential function of endogenously
produced IL-1, effects of IL-1Ra were assessed. Figure 1C demon-
strates that pre-incubation with IL-1Ra, even at 5 g/ml, was
unable to modulate IL-18BP expression in response to IFN-. As
expected, IL-1Ra completely suppressed IL-1-mediated IL-8 in
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this same set of experiments (Fig. 1D). Those data suggest that it
is very unlikely that endogenously produced IL-1 contributes to
IFN--induced IL-18BP expression in DLD-1 cells.
The role of the STAT1/GAS axis in IL-18BP 
promoter activation by DLD-1 cells
The transcriptional start site of IL-18BP was previously identified
[20]. Notably, a proximal GAS site imposes within the IL-18BP
promoter that is directly located adjacent to the transcriptional
start site (–25 bp to –33 bp relative to the transcriptional start site
at nt785 of AF110798). In addition, a second distal GAS site that
applies to the sequence requirements for putative GAS elements
[24, 25] is located at –625 bp to –633 bp. A third potential STAT1
binding site included in the promoter fragment used herein is an
IRF-E/ISRE-like site located at –54 bp to –69 bp. However, this site
is unlikely relevant in the context of the current study as it binds
ISGF3, a heterotrimeric transcription factor composed of
STAT1/STAT2/IRF9. Notably, STAT2 is activated by type I IFNs but
not by IFN- [24].
Luciferase reporter assays were performed in order to analyse
mechanisms that direct IL-18BP promoter activation under the
influence of IFN-. Figure 2A demonstrates strong induction of
the IL-18BP wild-type promoter (pGL3-BPwt) in response to 
IFN-. Promoter activation was significantly reduced in the 
context of a mutated proximal GAS site (pGL3-BPmt/prox). In
contrast, a dysfunctional distal GAS site (pGL3-BPmt/dist) left
reporter gene induction unaffected. The double mutation at the
proximal and the distal GAS site (pGL3-BPmt/prox/dist) was not
associated with further suppression of reporter gene activity as
compared to the single mutation at the proximal site (pGL3-
BPmt/prox). Those results clearly indicate that the integrity of the
proximal GAS site at the IL-18BP promoter is crucial for gene
activation in response to IFN-.
In accordance with previous data [22], robust activation of
STAT1 was obvious in DLD-1 cells under the influence of IFN-
(Fig. 2B). EMSA analysis was performed in order to identify 
in vitro protein/DNA interactions at the proximal GAS site of the 
IL-18BP promoter (Fig. 2C). For that purpose, double-stranded
DNA probes representing this specific site were exposed to
nuclear extracts generated from unstimulated or IFN--treated
cells. A single retarded complex (CI) was inducible by IFN-. No
such complex was detectable if extracts of unstimulated cells were
used. Formation of this particular complex, but not of the consti-
tutive complexes, was abolished by addition of two different
STAT1 antibodies suggesting an interaction between the labelled
probe representing this specific GAS site and pSTAT1 homod-
imers induced by IFN-. Notably, a super-shifted complex (CII)
became visible in case of co-incubation with the antibody obtained
from Santa Cruz (Fig. 2C, left panel, 5 g of protein). Figure 2C
(right panel, 1 g of protein) demonstrates impaired formation of
the otherwise retarded protein complex if oligonucleotides were
used in EMSA analysis that contain a mutation in the area reflect-
ing the specific proximal GAS site under investigation. For each
EMSA experiment, corresponding pSTAT1 immunoblot analysis
was performed and validated activation of STAT1 signalling by
IFN- (data not shown). We conclude that pSTAT1, present in
nuclei of IFN--activated DLD-1 cells, is able to bind in vitro to
oligonucleotides reflecting the specific nucleotide context at the
proximal GAS site of the IL-18BP promoter.
Based on those observations, we sought to assess by ChIP
analysis whether STAT1 is physically bound to this specific proxi-
mal GAS site in intact DLD-1 cells under the influence of IFN-. In
Fig. 2D (left panel), we demonstrate that a promoter fragment con-
taining the proximal GAS site and being targeted by the ChIP-PCR
is only amplified in those samples derived from sheared-chro-
matin that had been obtained from IFN--stimulated cells and
subsequently underwent STAT1 immunoprecipitation. No such
amplicons were generated by PCR if either sheared chromatin
from unstimulated cells was used or if immunoprecipitation was
performed with IgG control. These observations demonstrate that
activated STAT1 in fact physically binds to the proximal GAS site
of the IL-18BP promoter in DLD-1 cells exposed to IFN-. Figure 2D
(right panel) shows sheared chromatin of the experiment shown
in the left panel.
Modulation of STAT1 by siRNA impairs 
IFN--induced IL-18BP in DLD-1 cells
By using the siRNA approach, we set out to investigate the func-
tional significance of STAT1 for IL-18BP expression. In addition,
the role of IRF1 was investigated in these same experiments.
Figure 3A demonstrates efficient inhibition of STAT1 and IRF1 acti-
vation in DLD-1 cells that had been transfected with siRNA target-
ing STAT1 or IRF1 mRNA, respectively. In agreement with the role
of STAT1 in IRF1 induction [23], we also observed a reduction of
IRF1 expression in cells transfected with STAT1 siRNA. Whereas
reduction of IRF1 protein by IRF1 siRNA did not affect IL-18BP
expression, significant modulation was evident under the influ-
ence of siRNA targeting STAT1. However, although STAT1 siRNA
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Table 1 IL-18BP induction primarily detected in non-leucocytic cells
PBMC, THP-1 cells and DLD-1 cells were either kept as unstimulated
control or were stimulated with IFN- (PBMC, THP-1: 20 ng/ml; DLD-1:
10 ng/ml). After 12 hrs, IL-18BP mRNA was evaluated by realtime PCR.
IL-18BP mRNA was normalized to that of GAPDH. Data are expressed as
fold induction compared with unstimulated control 
 S.D., **P  0.01
compared to unstimulated control.
IFN
PBMC (n  5) 2.06 
 0.63
THP-1 (n  3) 2.52 
 0.48
DLD-1 (n  3) 16.54 
 3.77 **J. Cell. Mol. Med. Vol 13, No 8B, 2009
1991
was able to down-regulate STAT1 activation on average by 81.5%
(based on levels of nuclear pSTAT1), IL-18BP expression was
reduced by 48.9% only (Fig. 3B).
Discussion
In the present study, mechanisms underlying IFN--induced 
IL-18BP expression in the human colon carcinoma cell line DLD-1
were investigated. DLD-1 colon carcinoma cells are regarded as a
prototypic and well-characterized cell culture model for studying
gene regulation in colon epithelial cells under the influence of IFN-
[18, 22, 26, 27]. Moreover, it is well described that IL-18 bioac-
tivity likely contributes to colonic pathophysiology with regard to
inflammation and carcinogenesis [3, 13, 28, 29]. Here, we report
that STAT1, activated by IFN-, physically binds to a GAS element
located proximal at the IL-18BP promoter as detected by ChIP
analysis. Mutational analysis of luciferase reporter constructs fur-
ther substantiated the relevance of this particular regulatory site.
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Fig. 1 Optimal induction of IL-18BP in DLD-1 cells requires protein translation. (A) Cells were kept as unstimulated control, stimulated with IFN- (10
ng/ml) or with IL-1/TNF- (both 20 ng/ml) for 24 hrs. TCA-precipitated supernatants were analysed by immunoblot analysis. One representative of
three independently performed experiments is shown. (B) Cells were kept as unstimulated control or stimulated with CHX (10 g/ml), IFN- (10 ng/ml),
or CHX (10 g/ml)/IFN- (10 ng/ml). CHX was always added 2 hrs before IFN-. After 8 hrs, IL-18BP mRNA was evaluated by realtime PCR. IL-18BP
mRNA was normalized to that of GAPDH. Data are expressed as fold induction compared with unstimulated control 
 S.D. (n  3). **, P  0.01 com-
pared with unstimulated control or with cycloheximide alone; ##, P  0.01 compared with IFN- alone. Inset: DLD-1 cells were kept as unstimulated
control or stimulated as described above. After 1 hr, nuclear IRF1 was evaluated by immunoblot analysis. (C) DLD-1 cells were kept as unstimulated
control or stimulated for 12 hrs with IFN- (10 ng/ml) or with IFN- (10 ng/ml)/IL-1Ra (5 g/ml). IL-1Ra was always added 5 hrs before IFN-. 
IL-18BP mRNA was evaluated by realtime PCR. IL-18BP mRNA was normalized to that of GAPDH. Data are expressed as fold induction compared with
unstimulated control 
 S.D. (n  3). (D) Supernatants generated by the experiments shown in (C) were evaluated for IL-8 levels by ELISA. Additional
conditions: IL-1 (2 ng/ml) alone and IL-1 (2 ng/ml)/IL-1Ra (5 g/ml). Data are shown as mean 
 S.D. (n  3). **, P  0.01 compared with 
unstimulated control; ##, P  0.01 compared with IL-1.1992 © 2008 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 2 The role of the STAT1/GAS axis in IL-18BP promoter activation as detected in DLD-1 cells. (A) DLD-1 cells were transfected with the indicated
IL-18BP promoter constructs (pGL3-BPwt, pGL3-BPmt/prox, pGL3-BPmt/dist, pGL3-BPmt/prox/dist) together with pRL-TK (Promega) as described in
the ‘Materials and methods’ section. After 24 hrs, cells were kept as unstimulated control or stimulated with IFN- (20 ng/ml). After another 6 hrs, cells
were harvested and luciferase assays were performed. Data are expressed as mean fold-luciferase induction 
 S.D. (compared to the unstimulated con-
trol transfected with the same plasmid) obtained from three independently performed experiments. Black bars: unstimulated control cells, gray bars:
IFN- (20 ng/ml). *, P  0.05 and **, P  0.01 compared with the respective unstimulated control; ##, P  0.01 compared with pGL3-BPwt under
the influence of IFN-; $$, P  0.01 compared with pGL3-BPmt/dist under the influence of IFN-. (B) DLD-1 cells were kept as unstimulated control
or stimulated with IFN- (10 ng/ml) for the indicated times. Nuclear pSTAT1 was evaluated by immunoblot analysis. One representative of three inde-
pendently performed experiments is shown. (C) Cells were kept as unstimulated control or stimulated with IFN- (10 ng/ml). After 1 hr, nuclear lysates
were prepared and protein binding to oligonucleotides reflecting the proximal GAS site (–18 bp/–40 bp) was assessed by electrophoretic mobility shift
assay analysis. Where indicated, anti-STAT1 antibodies were added to characterize the IFN--inducible retarded complex denoted CI. FP, free probe; CII,
supershifted complex. One representative of six independently performed experiments is shown. Right panel: protein binding to wild-type oligonu-
cleotides was compared with binding to the mutated oligonucleotides GASprox-5	mut and GASprox-3	mut, respectively. One representative of three
independently performed experiments is shown. (D) DLD-1 cells were kept as unstimulated control or stimulated with IFN- (10 ng/ml). After 1 hr, cells
were harvested followed by ChIP analyses as described in the ‘Materials and methods’ section. One representative of six independently performed exper-
iments is shown (left panel). Right panel: sheared chromatin of the experiment shown in the left panel.J. Cell. Mol. Med. Vol 13, No 8B, 2009
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In fact, activation of GAS elements by STAT1 homodimers is key
to IFN- biological activity and mediates induction of numerous
genes [24]. Notably, significant induction of IL-18BP in DLD-1 cells
was achieved in the absence of translation, though optimal gene
activation required protein synthesis. Those observations were
complemented by use of the siRNA technology and altogether
strongly suggest a direct and pivotal role of STAT1 in 
IL-18BP regulation as observed in DLD-1 cells. Notably, we could
recently demonstrate that STAT3 activation has no influence on 
IL-18BP expression [22].
Data presented herein reveal cell type specificity concerning
the usage of the key GAS element at the proximal IL-18BP pro-
moter. In fact, a previous study likewise identified this same prox-
imal GAS site as crucial for IFN--induced IL-18BP in HepG2 cells.
However, in those cells, instead of STAT1, a complex consisting of
IRF1 and C/EBP is binding to the specific GAS site under inves-
tigation [20]. Whereas C/EBP is constitutively expressed in most
cell types [30], IRF1 biological activity is dependent on de novo
protein synthesis and up-regulated by IFN- [23]. Consequently,
induction of IL-18BP in response to IFN- is fully dependent on
translation in HepG2 cells [20]. In contrast, a mandatory role for
IRF1 in the up-regulation of IL-18BP by DLD-1 cells appears
unlikely in light of significant IL-18BP induction under blockage of
translation and of results obtained in the context of IRF1 silencing.
Furthermore, only a single IFN--induced retarded complex
became apparent in EMSA analysis and was identified as being at
least partially composed of STAT1. Differences between DLD-1
and HepG2 cells may relate to a divergent repertoire of transcrip-
tion factors. Interestingly, compared to DLD-1 cells, HepG2 cells
express higher levels of C/EBP (data not shown). Therefore, it is
tempting to speculate that, once IRF1 is induced by IFN-, STAT1
homodimers and IRF1:C/EBP heterodimers compete for binding
to this particular GAS element at the proximal IL-18BP promoter.
Data presented in the current study also indicate that mecha-
nisms besides binding of STAT1 to the proximal GAS site affect the
extent of IL-18BP promoter activation. Not only was most efficient
induction of IL-18BP dependent on protein synthesis, mutational
analysis in luciferase-reporter assays and siRNA experiments tar-
geting STAT1 further suggest that additional mechanisms contribute
to IFN--induced IL-18BP gene activation. Those likely STAT1-inde-
pendent actions of IFN- are currently under investigation. Among
signalling pathways that possibly synergize with STAT1 are those
culminating in NF-
B activation [31, 32]. In fact it has been demon-
strated that endogenously produced IL-1 and subsequent NF-
B
activation must be regarded a cofactor for IL-18BP production in
Wistar Institute Susan Hayflick (WISH) cells and HaCaT ker-
atinocytes [21]. However, a basal level of NF-
B activity is charac-
teristic for DLD-1 cells [22, 33, 34] and may be related to the inabil-
ity of IL-1Ra to modulate IFN--induced IL-18BP in this cell type.
Taken together, data presented herein demonstrate a direct
action of STAT1 on the proximal GAS site of the IL-18BP promoter
that is crucial for gene induction as detected in DLD-1 cells.
Furthermore, present and previous observations support a con-
cept of cell type specific, promiscuous usage of GAS elements by
either STAT1 homodimes or IRF1:C/EBP heterodimers at a given
IFN--inducible promoter.
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Fig. 3 Modulation of STAT1 by siRNA impairs IFN--induced IL-18BP
in DLD-1 cells. (A) DLD-1 cells were either mock transfected or trans-
fected with the indicated siRNA. After 2d, cells were stimulated with
IFN- (10 ng/ml) for 1 hr. Nuclear pSTAT1, total STAT1 and IRF1 con-
tent was assessed by immunoblot analysis. One representative of three
independently performed experiments is shown. (B) IL-18BP expres-
sion by cells treated as described in (A) but stimulated for 8 hrs was
evaluated by realtime PCR. IL-18BP mRNA was normalized to that of
GAPDH. Data are expressed as% of mock-transfected IFN--stimulated
cells 
 S.D.; for mock transfection, STAT1 siRNA, control siRNA: n  6;
for IRF1 siRNA: n  3. **, P  0.01 compared to mock-transfected
IFN- stimulated cells.1994
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